the expert’s report won’t really help as it is written to support the board approach - I know they are independent but they opine on what’s fair and reasonable and as the board isn’t pushing to extract more value or object (see Origin defence and monetisation strategy) then there won’t be much more methinks - unless another party comes in. I genuinely want to see detail on staff and the reference to Hancock must be explained - it isn’t a condition but sits very oddly with the proposed SOA. Clearly they are in it but that means more money available. There is far more info to be revealed. Let’s hope STO comes in. I am a very small holder but sad to see another company crumble and at such a small increase. it’s the lack of detail that’s concerning - I am not suggesting impropriety but it’s a poor deal for shareholders.
- Forums
- ASX - By Stock
- SXY
- Ann: Improved POSCO proposal and intention to recommend
Ann: Improved POSCO proposal and intention to recommend, page-51
-
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SXY (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online